CAR-T Cell Therapy in China
Overview
CAR-T cell therapy re-engineers a patient’s own T lymphocytes to recognize and attack their cancer. It has produced remarkable remissions in relapsed and refractory leukemias, lymphomas and myeloma after conventional therapy has failed.
Chinese centers were among the world’s first to run pivotal CAR-T trials and have treated thousands of patients; domestically developed CAR-T products are approved and available, in several cases years ahead of some international markets.
Symptoms & Signs
Symptoms are those of the underlying blood cancer: recurrent fevers and night sweats
Progressive fatigue and anemia despite treatment
Swollen lymph nodes or an enlarging abdomen from lymph-node or marrow disease
Frequent infections from impaired immunity
Bone pain from marrow infiltration
Disease that relapses after, or fails to respond to, two or more prior lines of therapy — the classic CAR-T indication
Diagnosis
Re-staging of the underlying malignancy: PET-CT for lymphoma, marrow studies for leukemia
Marrow biopsy confirming disease and cell-of-origin
Molecular testing — clonality, cytogenetics and targeted NGS panels
Assessment of heart, lung, kidney and liver function required before cell therapy
Screening for active infection, which must be controlled first
HLA and general transplant-compatibility review
Treatment Options
Leukapheresis collecting the patient’s T cells for engineering
Lymphodepleting chemotherapy preparing the body for CAR-T infusion
Single CAR-T infusion, followed by inpatient monitoring for cytokine-release syndrome and neurotoxicity
Management of side effects with tocilizumab-class and steroid protocols
Post-infusion surveillance: CAR-T persistence testing and disease monitoring
Salvage planning including allogeneic transplant for eligible patients after CAR-T
Advanced Technologies & Novel Drug
Domestically developed CD19 CAR-T products approved for lymphoma and leukemia
BCMA-directed CAR-T for multiple myeloma
GMP cell-processing laboratories with closed manufacturing systems
Cytokine-release-syndrome prediction and neurotoxicity monitoring protocols
Novel dual-target and armored CAR constructs in clinical programs at Chinese centers
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Peking University People's Hospital — Beijing
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin
- Ren Xiu Bao — Department of Biotherapy
- Cao Shui — Department of Biotherapy
- Zhang Xin Wei — Department of Biotherapy
- Wei Li Hui — Gynecology